A Phase II Study Using Alemtuzumab Combined With Fludarabine for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL).

Trial Profile

A Phase II Study Using Alemtuzumab Combined With Fludarabine for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL).

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2016

At a glance

  • Drugs Alemtuzumab (Primary) ; Fludarabine (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms ECO-1
  • Sponsors Genzyme Corporation
  • Most Recent Events

    • 01 Dec 2011 Company added as trial sponsor as reported by ClinicalTrials.gov.
    • 08 Dec 2010 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
    • 08 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top